ARS Pharmaceuticals, Inc.(SPRY)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,777 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SPRY Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ARS Pharmaceuticals, Inc. (SPRY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SPRY at 20.3/100 on a 32-signal composite quality model, placing it at rank #2,777 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.7) and free cash flow (5.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ARS Pharmaceuticals, Inc. reports quarterly revenue of $33.7M, net income of $-62.3M, free cash flow of $-60.9M. Top institutional holders of SPRY by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management, ORBIMED ADVISORS, based on the most recent SEC filings. SPRY trades on the Nasdaq exchange and files with the SEC under CIK 1671858. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPRY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARS Pharmaceuticals, Inc. directly from SEC EDGAR. ARS Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 4 and 33 since 2023, currently 20.3 — a declining long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$33.7M
Net Income
Q2 2026
$-62.3M
Free Cash Flow
Q2 2026
$-60.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-5.5% YoYNet Income
-2241.8% YoYOperating Income
-5720.6% YoYEPS (Diluted)
-2275.0% YoYTotal Assets
-6.7% YoYTotal Debt
Op. Cash Flow
-1361.2% YoYFree Cash Flow
-1418.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $84.3M -5.5% | $89.1M +297063.3% | $30.0K -97.7% | $1.3M -76.1% | $5.5M | — |
| Net Income | $-171.3M -2241.8% | $8.0M +114.7% | $-54.4M -56.8% | $-34.7M -71.3% | $-20.2M +38.6% | $-32.9M |
| Operating Income | $-179.4M -5720.6% | $-3.1M +95.4% | $-67.5M -90.1% | $-35.5M -82.6% | $-19.5M +40.9% | $-32.9M |
| EPS (Diluted) | $-1.74 -2275.0% | $0.08 +114.0% | $-0.57 +34.5% | $-0.87 -24.3% | $-0.70 | — |
| Total Assets | $327.7M -6.7% | $351.2M +50.6% | $233.2M -17.1% | $281.4M -15.6% | $333.5M -15.5% | $394.8M |
| Total Debt | $96.4M | $0.00 | — | — | — | — |
| Operating Cash Flow | $-170.9M -1361.2% | $13.5M +122.9% | $-59.3M -47.9% | $-40.1M -128.2% | $-17.6M +43.7% | $-31.2M |
| Free Cash Flow | $-171.2M -1418.5% | $13.0M +121.8% | $-59.4M -47.6% | $-40.3M -128.6% | $-17.6M +45.1% | $-32.1M |
Get alerted when SPRY's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ARS Pharmaceuticals, Inc. including:
Top Institutional Holders of SPRY
RA CAPITAL MANAGEMENT, L.P.
$87.0M10,860,977 shRubric Capital Management LP
$68.4M8,540,861 shORBIMED ADVISORS LLC
$66.4M8,288,510 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$60.1M7,503,812 shBlackRock, Inc.
$42.5M5,311,319 shTyro Capital Management LLC
$35.7M4,459,337 shabrdn plc
$33.4M4,170,629 shSR ONE CAPITAL MANAGEMENT, LP
$32.1M4,012,903 shSTATE STREET CORP
$29.9M3,730,623 shCapital World Investors
$22.1M2,754,931 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $87.0M | 10,860,977 |
| Rubric Capital Management LP | $68.4M | 8,540,861 |
| ORBIMED ADVISORS LLC | $66.4M | 8,288,510 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $60.1M | 7,503,812 |
| BlackRock, Inc. | $42.5M | 5,311,319 |
| Tyro Capital Management LLC | $35.7M | 4,459,337 |
| abrdn plc | $33.4M | 4,170,629 |
| SR ONE CAPITAL MANAGEMENT, LP | $32.1M | 4,012,903 |
| STATE STREET CORP | $29.9M | 3,730,623 |
| Capital World Investors | $22.1M | 2,754,931 |
Companies Similar to SPRY
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Syndax Pharmaceuticals Inc
BICYCLE THERAPEUTICS PLC
AGIOS PHARMACEUTICALS, INC.
UroGen Pharma Ltd.
Kura Oncology, Inc.
Foghorn Therapeutics Inc.
PROCEPT BioRobotics Corp
ARDELYX, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SPRY on your watchlist
Track score changes the day ARS Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SPRY a good stock to buy?
13F Pro's AI-powered analysis of ARS Pharmaceuticals, Inc. (SPRY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SPRY are available on the SPRY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SPRY is classified as a small company.
Which hedge funds own SPRY?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SPRY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARS Pharmaceuticals, Inc.'s investment landscape.